UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,947 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 293,927 shares of the biopharmaceutical company's stock after selling 27,947 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.19% of TG Therapeutics worth $6,875,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Oppenheimer & Co. Inc. bought a new stake in shares of TG Therapeutics during the third quarter worth about $759,000. Segall Bryant & Hamill LLC acquired a new position in shares of TG Therapeutics during the third quarter worth $1,225,000. Principal Financial Group Inc. grew its stake in shares of TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in TG Therapeutics in the second quarter valued at $8,698,000. Finally, Marshall Wace LLP bought a new position in TG Therapeutics during the 2nd quarter worth $36,501,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Stock Down 3.6 %

NASDAQ TGTX traded down $1.17 on Tuesday, reaching $31.67. The company had a trading volume of 2,638,407 shares, compared to its average volume of 3,626,240. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company's fifty day moving average is $28.01 and its 200 day moving average is $23.14. TG Therapeutics, Inc. has a 52-week low of $12.84 and a 52-week high of $36.84. The stock has a market capitalization of $4.93 billion, a P/E ratio of -316.67 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same period in the previous year, the business earned $0.73 earnings per share. The firm's revenue for the quarter was down 49.4% on a year-over-year basis. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TGTX. StockNews.com lowered TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday. HC Wainwright upped their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a report on Monday, November 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.50% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.